Medicilon Assists Longsee Biomedical's LF01 capsules approved for clinical use
Medicilon
  • Reads 1
  • Votes 0
  • Parts 1
  • Time <5 mins
  • Reads 1
  • Votes 0
  • Parts 1
  • Time <5 mins
Medicilon
Ongoing, First published Dec 08, 2023
lf01
On November 20, LF01, an innovative anti-tumor drug independently developed by Longsee Biomedical Co. Ltd. (Longsee Biomedical), received the NMPA drug clinical trial approval notice.
All Rights Reserved
lf01
Table of contents

1 part

Sign up to add Medicilon Assists Longsee Biomedical's LF01 capsules approved for clinical use to your library and receive updates
or
Content Guidelines
You may also like
Lorem_Ipsum_Wp Take 14 by sohanmotwanistaff
3 parts Ongoing
Just another test story
You may also like
Slide 1 of 1
Lorem_Ipsum_Wp Take 14 cover

Lorem_Ipsum_Wp Take 14

3 parts Ongoing

Just another test story

More details